To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and for other purposes.
USA115th CongressHR-4117| House
| Updated: 10/27/2017
Lloyd Doggett
Democratic Representative
Texas
Cosponsors (37)
Marcy Kaptur (Democratic)Ruben Gallego (Democratic)Raúl M. Grijalva (Democratic)Mark Pocan (Democratic)Karen Bass (Democratic)James R. Langevin (Democratic)David N. Cicilline (Democratic)Emanuel Cleaver (Democratic)Carol Shea-Porter (Democratic)Steve Cohen (Democratic)Rosa L. DeLauro (Democratic)Vicente Gonzalez (Democratic)Ro Khanna (Democratic)Al Green (Democratic)Matt Cartwright (Democratic)John B. Larson (Democratic)Mark DeSaulnier (Democratic)Keith Ellison (Democratic)John Conyers (Democratic)Jerrold Nadler (Democratic)Luis V. Gutierrez (Democratic)Pramila Jayapal (Democratic)Kathy Castor (Democratic)Eleanor Holmes Norton (Democratic)Jamie Raskin (Democratic)Elijah E. Cummings (Democratic)Janice D. Schakowsky (Democratic)Maxine Waters (Democratic)Nydia M. Velázquez (Democratic)Beto O'Rourke (Democratic)Peter Welch (Democratic)Bennie G. Thompson (Democratic)Earl Blumenauer (Democratic)Gwen Moore (Democratic)Chellie Pingree (Democratic)Grace F. Napolitano (Democratic)Judy Chu (Democratic)
Ways and Means Committee, Commerce, Manufacturing, and Trade Subcommittee, Judiciary Committee, Energy and Commerce Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Competitive Deals Resulting in Unleashed Generics and Savings Act of 2017 or the Competitive DRUGS Act of 2017 This bill establishes a series of requirements and prohibitions regarding certain patent infringement agreements between brand name and generic drug manufacturers in which the generic drug manufacturer agrees to delay the availability of applicable generic drugs. Among other things, the bill specifies that such agreements constitute an unfair method of competition and are subject to specified civil penalties.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the Committee on Ways and Means, and in addition to the Committees on the Judiciary, and Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Digital Commerce and Consumer Protection.
Health
Administrative remediesBusiness expensesCivil actions and liabilityCompetition and antitrustFederal Trade Commission (FTC)Income tax deductionsIntellectual propertyJudicial review and appealsMarketing and advertisingPrescription drugsResearch and development
To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and for other purposes.
USA115th CongressHR-4117| House
| Updated: 10/27/2017
Competitive Deals Resulting in Unleashed Generics and Savings Act of 2017 or the Competitive DRUGS Act of 2017 This bill establishes a series of requirements and prohibitions regarding certain patent infringement agreements between brand name and generic drug manufacturers in which the generic drug manufacturer agrees to delay the availability of applicable generic drugs. Among other things, the bill specifies that such agreements constitute an unfair method of competition and are subject to specified civil penalties.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the Committee on Ways and Means, and in addition to the Committees on the Judiciary, and Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Digital Commerce and Consumer Protection.
Lloyd Doggett
Democratic Representative
Texas
Cosponsors (37)
Marcy Kaptur (Democratic)Ruben Gallego (Democratic)Raúl M. Grijalva (Democratic)Mark Pocan (Democratic)Karen Bass (Democratic)James R. Langevin (Democratic)David N. Cicilline (Democratic)Emanuel Cleaver (Democratic)Carol Shea-Porter (Democratic)Steve Cohen (Democratic)Rosa L. DeLauro (Democratic)Vicente Gonzalez (Democratic)Ro Khanna (Democratic)Al Green (Democratic)Matt Cartwright (Democratic)John B. Larson (Democratic)Mark DeSaulnier (Democratic)Keith Ellison (Democratic)John Conyers (Democratic)Jerrold Nadler (Democratic)Luis V. Gutierrez (Democratic)Pramila Jayapal (Democratic)Kathy Castor (Democratic)Eleanor Holmes Norton (Democratic)Jamie Raskin (Democratic)Elijah E. Cummings (Democratic)Janice D. Schakowsky (Democratic)Maxine Waters (Democratic)Nydia M. Velázquez (Democratic)Beto O'Rourke (Democratic)Peter Welch (Democratic)Bennie G. Thompson (Democratic)Earl Blumenauer (Democratic)Gwen Moore (Democratic)Chellie Pingree (Democratic)Grace F. Napolitano (Democratic)Judy Chu (Democratic)
Ways and Means Committee, Commerce, Manufacturing, and Trade Subcommittee, Judiciary Committee, Energy and Commerce Committee
Health
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Administrative remediesBusiness expensesCivil actions and liabilityCompetition and antitrustFederal Trade Commission (FTC)Income tax deductionsIntellectual propertyJudicial review and appealsMarketing and advertisingPrescription drugsResearch and development